Thursday's Headlines: ‘A gut politician’: Trump’s go-to negotiating tactics not working in standoff
Trump walks out of meeting after Democrats reject wall funds; 8 House Republicans break with Trump on shutdown strategy, back Democrats' plan to reopen Treasury; The history of...
Democracy Dies in Darkness
The morning's most important stories, selected by Post editors
Lawmakers of both parties are frustrated by the president's vacillating approach as he demands a portion of his border wall in exchange for reopening the government.
White House negotiations about the shutdown collapsed into acrimony and disarray, with President Trump calling the talks "a total waste of time" and Senate Minority Leader Charles E. Schumer calling Trump's actions "a temper tantrum."
By Erica Werner, Sean Sullivan, Mike DeBonis and Seung Min Kim • Read more »
The Republicans voted to support a measure that would fund the IRS and other agencies whose workers have been furloughed or working without pay. The bill is unlikely to pass in the Senate.
Following President Trump's nationally televised plea to build a border wall, we look at the modern history of the arrest of migrants attempting to enter the United States without authorization.
By Brittany Mayes, Aaron Williams and Laris Karklis • Read more »
The team is gearing up to prevent President Trump's confidential discussions with advisers from being disclosed to House Democratic investigators and revealed in the special counsel's report, setting the stage for protracted legal standoffs that may reach the Supreme Court.
Some Democrats, concerned about potential bias regarding the special counsel's investigation, say they are being blocked from speaking to the nominee because of the shutdown.
By Karoun Demirjian, Seung Min Kim and Devlin Barrett • Read more »
The former prominent archbishop of Washington now faces the prospect of soon being defrocked — meaning he would no longer be a priest of the Catholic Church and would lose his church housing and financial support.
By Michelle Boorstein, Julie Zauzmer and Chico Harlan • Read more »
Doctors, drug firms and the nation's top drug regulator say the companies that make costly name-brand biologic drugs, which are grown from living cells, are sowing doubt about the wisdom of switching to generic versions — even though the FDA has certified they are safe and effective.
Should justices overturn a precedent that says states can be sued in other states without their consent? The case is a key test of a concept called stare decisis, or respecting past decisions, for the court's strengthened conservative majority.
Twitter
Facebook
No comments:
Post a Comment